Hkb il1b

Manufactured by InvivoGen

Sourced in United States

Hkb-il1b is a laboratory product that functions as a recombinant human interleukin-1 beta protein. It is intended for research use only.

Automatically generated - may contain errors

Lab products found in correlation

Human il 6, by R&D Systems (1 mentions) Hek blue il 1β cells, by InvivoGen (1 mentions) Human il 1β, by Thermo Fisher Scientific (1 mentions) Quanti blue assay, by InvivoGen (1 mentions) Human il 1ra, by Thermo Fisher Scientific (1 mentions) G csf, by R&D Systems (1 mentions) Il 1ra, by InvivoGen (1 mentions) Human il 1α, by Thermo Fisher Scientific (1 mentions) Mrc 5 lung fibroblasts, by American Type Culture Collection (1 mentions)

2 protocols using hkb il1b

Detecting IL-1-Induced NF-κB Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used HEK-Blue™ IL-1β cells that respond specifically to IL-1 (# hkb-il1b, InvivoGen). These cells can detect IL-1α and IL-1β, as these cytokines bind to the same receptor, IL-1R1. They express a Seap reporter gene under the control of the IFN-β minimal promoter fused to five NF-kappaB and five AP-1 binding sites. Thirty microliters (300,000 cells/ml) per well of a 384-well plate were plated overnight. Cells were then stimulated with graded concentrations of cytokines (hIL-1α or hIL-1β) in the absence or presence of canakinumab (Ilaris®, ILARI LYVI 150MG 22GLW.012, batch U003 0409)^{22 (link)}, anakinra (Kineret®, 100 mg/0.67 ml injectable solution, Sobi)^{23 (link)}, or compound (S)-2 (compounds were pre-mixed for 1 h with the cytokine prior to addition to cells) and further incubated overnight before assessment of Seap activity.

Hommel U., Hurth K., Rondeau J.M., Vulpetti A., Ostermeier D., Boettcher A., Brady J.P., Hediger M., Lehmann S., Koch E., Blechschmidt A., Yamamoto R., Tundo Dottorello V., Haenni-Holzinger S., Kaiser C., Lehr P., Lingel A., Mureddu L., Schleberger C., Blank J., Ramage P., Freuler F., Eder J, & Bornancin F. (2023). Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β. Nature Communications, 14, 5497.

+ Open protocol

+ Expand

Evaluating IL-1RA and Antibody Therapy in Cell-Based Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

40pg/uL human IL-1RA (PeproTech, US) was pre-incubated with 5ng/uL antibody (G4–21 or isotype control. IL-1RA and antibody were applied to HEK-Blue IL-1β cells (InvivoGen, US) for 2 hours and stimulated with 2pg/uL human IL-1β (PeproTech, US) for 36 hours at 37°C. Alternatively, cells were treated with 8–10 nM IL-1RA and commercial monoclonal (mAbs) or polyclonal antibodies (pAbs) at 40–2000nM, or with patient plasma at 1:10 and 1:20 dilutions, and subsequently stimulated with 0.1–1 nM IL-1β for 24 hours. Cells were treated with antibodies in the presence of IL-1α and IL-1RA, IL-1RA alone, or media, and supernatants assayed using the QUANTI-Blue assay (InvivoGen, hkb-il1b, US).
Human A549 lung epithelial cells and MRC-5 lung fibroblasts (ATCC, US) were treated with 10nM IL-1RA and patient plasma and stimulated with 0.5nM human IL-1α (PeproTech, US) for 24 hours at 37°C. RNA was isolated, cDNA prepared, and samples analyzed using TaqMan FAM-conjugated primer sets. Supernatants were collected and assayed for human IL-6 (R&D, US), IL-8 (R&D, US), and G-CSF (R&D, US) via ELISA.

Jarrell J.A., Baker M.C., Perugino C.A., Liu H., Bloom M.S., Maehara T., Wong H.H., Lanz T., Adamska J.Z., Kongpachith S., Sokolove J., Stone J.H., Pillai S.S, & Robinson W.H. (2021). Neutralizing Anti-Interleukin-1 Receptor-Antagonist Autoantibodies Induce Inflammatory and Fibrotic Mediators in IgG4-Related Disease. The Journal of allergy and clinical immunology, 149(1), 358-368.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!